HRP20240276T1 - 3-beta-(4-metoksibenzilloksi)pregn-5-en-20-on za uporabu u liječenju poremećaja povezanih s kanabinoidima - Google Patents
3-beta-(4-metoksibenzilloksi)pregn-5-en-20-on za uporabu u liječenju poremećaja povezanih s kanabinoidima Download PDFInfo
- Publication number
- HRP20240276T1 HRP20240276T1 HRP20240276TT HRP20240276T HRP20240276T1 HR P20240276 T1 HRP20240276 T1 HR P20240276T1 HR P20240276T T HRP20240276T T HR P20240276TT HR P20240276 T HRP20240276 T HR P20240276T HR P20240276 T1 HRP20240276 T1 HR P20240276T1
- Authority
- HR
- Croatia
- Prior art keywords
- cannabinoid
- compound
- use according
- disorder
- related disorder
- Prior art date
Links
- 229930003827 cannabinoid Natural products 0.000 title claims 28
- 239000003557 cannabinoid Substances 0.000 title claims 28
- 229940065144 cannabinoids Drugs 0.000 title claims 5
- AAZPIQPULVRHOW-SFKJMYEFSA-N 1-[(3S,8S,9S,10R,13S,14S,17S)-3-[(4-methoxyphenyl)methoxy]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound COC1=CC=C(CO[C@@H]2CC3=CC[C@H]4[C@@H]5CC[C@H](C(C)=O)[C@]5(CC[C@@H]4[C@]3(CC2)C)C)C=C1 AAZPIQPULVRHOW-SFKJMYEFSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 208000025517 cannabinoid hyperemesis syndrome Diseases 0.000 claims 2
- 206010007776 catatonia Diseases 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000035987 intoxication Effects 0.000 claims 2
- 231100000566 intoxication Toxicity 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims 1
- 241000218236 Cannabis Species 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 235000005687 corn oil Nutrition 0.000 claims 1
- 239000002285 corn oil Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Claims (17)
1. Jedinjenje prema formuli (I):
[image]
za primjenu u liječenju poremećaja povezanih s kanabinoidima.
2. Jedinjenje za primjenu prema zahtjevu 1 naznačeno time što poremećaj povezan s kanabinoidima može biti poremećaj upotrebe kanabinoida; intoksikacija kanabinoidima; odvikavanje od kanabinoida; drugi poremećaji uzrokovani kanabinoidima; nespecificirani poremećaj povezan s kanabinoidima; sindrom kanabinoidne hiperemeze; katatonija izazvana kanabinoidima.
3. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima poremećaj upotrebe kanabinoida.
4. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima intoksikacija kanabinoidima.
5. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima odvikavanje od kanabinoida.
6. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima drugi poremećaj uzrokovan kanabinoidima koji može biti poremećaj anksioznosti uzrokovan kanabinoidima, psihotični poremećaj uzrokovan kanabinoidima, poremećaj spavanja uzrokovan kanabinoidima, delirijum izazvan intoksikacijom kanabinoidima.
7. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima nespecificirani poremećaj povezan s kanabinoidima.
8. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima sindrom kanabinoidne hiperemeze.
9. Jedinjenje za primjenu prema zahtjevima 1 ili 2 naznačeno time što je poremećaj povezan s kanabinoidima katatonija izazvana kanabinoidima.
10. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što su kanabinoidi izvedeni iz biljke Cannabis L.
11. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što su kanabinoidi sintetička jedinjenja sa agonističkim djelovanjem na receptore CB1.
12. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što se navedeno jedinjenje daje subjektu oralnim putem.
13. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što se navedeno jedinjenje daje subjektu parenteralnim putem u vidu formulacije koja se odmah apsorbira ili formulacije sa postepenim otpuštanjem.
14. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što se navedeno jedinjenje daje subjektu intravenoznim ili subkutanim putem ili intramuskularnim putem.
15. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što se navedeno jedinjenje primjenjuje intranazalno ili inhalacijom ili sublingvalno ili topikalno ili transdermalno ili u vidu supozitorija ili pesara.
16. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što se navedeno jedinjenje daje subjektu u dozi od 1 mg do 1000 mg.
17. Jedinjenje za primjenu prema bilo kojem od prethodnih zahtjeva naznačeno time što se navedeno jedinjenje primjenjuje u uljnom nosaču, kao što su biljna ulja koja sadrže trigliceride dugog lanca, po mogućnosti kukuruzno ulje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305177 | 2018-02-20 | ||
| PCT/EP2019/054217 WO2019162328A1 (en) | 2018-02-20 | 2019-02-20 | 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders |
| EP19705190.7A EP3755339B1 (en) | 2018-02-20 | 2019-02-20 | 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240276T1 true HRP20240276T1 (hr) | 2024-05-10 |
Family
ID=61283142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240276TT HRP20240276T1 (hr) | 2018-02-20 | 2019-02-20 | 3-beta-(4-metoksibenzilloksi)pregn-5-en-20-on za uporabu u liječenju poremećaja povezanih s kanabinoidima |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11484537B2 (hr) |
| EP (1) | EP3755339B1 (hr) |
| JP (1) | JP7254100B2 (hr) |
| KR (1) | KR20200122324A (hr) |
| CN (1) | CN111757740B (hr) |
| AU (1) | AU2019223049A1 (hr) |
| BR (1) | BR112020017026A2 (hr) |
| CA (1) | CA3090975C (hr) |
| CL (1) | CL2020002147A1 (hr) |
| DK (1) | DK3755339T3 (hr) |
| FI (1) | FI3755339T3 (hr) |
| HR (1) | HRP20240276T1 (hr) |
| IL (1) | IL276697B1 (hr) |
| LT (1) | LT3755339T (hr) |
| MA (1) | MA51891B1 (hr) |
| MX (1) | MX2020008687A (hr) |
| PL (1) | PL3755339T3 (hr) |
| PT (1) | PT3755339T (hr) |
| RS (1) | RS65281B1 (hr) |
| WO (1) | WO2019162328A1 (hr) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006110545A (ru) * | 2003-09-02 | 2007-10-10 | Зольвай Фармасьютикалз Гмбх (De) | Новое медицинское применение избирательных антагонистов св1-рецептора |
| PT2709631T (pt) | 2011-05-20 | 2017-04-19 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Antagonistas de receptor de cb1 |
| SI2925770T1 (sl) * | 2012-11-28 | 2017-07-31 | Institut National De La Sante Et De La Recherche Medicale(Inserm) | 3-(4'-substituirani)-benzil-eter derivati pregnenolona |
-
2019
- 2019-02-20 DK DK19705190.7T patent/DK3755339T3/da active
- 2019-02-20 CA CA3090975A patent/CA3090975C/en active Active
- 2019-02-20 WO PCT/EP2019/054217 patent/WO2019162328A1/en active Application Filing
- 2019-02-20 BR BR112020017026-7A patent/BR112020017026A2/pt unknown
- 2019-02-20 JP JP2020566324A patent/JP7254100B2/ja active Active
- 2019-02-20 FI FIEP19705190.7T patent/FI3755339T3/fi active
- 2019-02-20 PL PL19705190.7T patent/PL3755339T3/pl unknown
- 2019-02-20 US US16/968,237 patent/US11484537B2/en active Active
- 2019-02-20 AU AU2019223049A patent/AU2019223049A1/en active Pending
- 2019-02-20 MX MX2020008687A patent/MX2020008687A/es unknown
- 2019-02-20 PT PT197051907T patent/PT3755339T/pt unknown
- 2019-02-20 CN CN201980013958.5A patent/CN111757740B/zh active Active
- 2019-02-20 LT LTEPPCT/EP2019/054217T patent/LT3755339T/lt unknown
- 2019-02-20 MA MA51891A patent/MA51891B1/fr unknown
- 2019-02-20 EP EP19705190.7A patent/EP3755339B1/en active Active
- 2019-02-20 IL IL276697A patent/IL276697B1/en unknown
- 2019-02-20 KR KR1020207024076A patent/KR20200122324A/ko not_active Application Discontinuation
- 2019-02-20 RS RS20240255A patent/RS65281B1/sr unknown
- 2019-02-20 HR HRP20240276TT patent/HRP20240276T1/hr unknown
-
2020
- 2020-08-19 CL CL2020002147A patent/CL2020002147A1/es unknown
-
2022
- 2022-09-15 US US17/945,339 patent/US20230226076A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL276697B1 (en) | 2024-04-01 |
| US20210030768A1 (en) | 2021-02-04 |
| RU2020130586A (ru) | 2022-03-22 |
| MX2020008687A (es) | 2020-09-25 |
| CA3090975C (en) | 2024-01-09 |
| BR112020017026A2 (pt) | 2020-12-15 |
| MA51891A (fr) | 2021-05-26 |
| CA3090975A1 (en) | 2019-08-29 |
| KR20200122324A (ko) | 2020-10-27 |
| IL276697A (en) | 2020-09-30 |
| PL3755339T3 (pl) | 2024-04-22 |
| RS65281B1 (sr) | 2024-03-29 |
| CN111757740B (zh) | 2023-12-15 |
| MA51891B1 (fr) | 2024-03-29 |
| CN111757740A (zh) | 2020-10-09 |
| EP3755339A1 (en) | 2020-12-30 |
| DK3755339T3 (da) | 2024-02-26 |
| EP3755339B1 (en) | 2024-01-03 |
| US20230226076A1 (en) | 2023-07-20 |
| WO2019162328A1 (en) | 2019-08-29 |
| JP7254100B2 (ja) | 2023-04-07 |
| PT3755339T (pt) | 2024-02-26 |
| JP2021514009A (ja) | 2021-06-03 |
| US11484537B2 (en) | 2022-11-01 |
| AU2019223049A1 (en) | 2020-08-13 |
| CL2020002147A1 (es) | 2021-01-15 |
| LT3755339T (lt) | 2024-03-25 |
| FI3755339T3 (fi) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY196526A (en) | Non-Racemic Beta-Hydroxybutyrate Compounds and Compositions Enriched With The R-Enantiomer And Methods Of Use | |
| EA201000024A1 (ru) | Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1 | |
| MA32231B1 (fr) | Composés organiques | |
| HRP20192266T1 (hr) | Kompozicije i postupci za nekirurško liječenje ptoze | |
| MX2015012302A (es) | Composiciones tópicas y métodos de tratamiento para trastornos de la piel. | |
| EA201270045A1 (ru) | Применение неофитадиена в качестве добавки для жидких сигарет | |
| NZ709486A (en) | Solid solution compositions and use in chronic inflammation | |
| MA38385A1 (fr) | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) | |
| BRPI0910182A2 (pt) | composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto" | |
| BR112015019683A2 (pt) | óleo para máquina de refrigeração, e composição do fluido de trabalho para máquinas de refrigeração | |
| BRPI0516482A (pt) | 2, 6-substituìda-4-monossubstituìda-amino-pirimidina como antagonistas receptor de prostaglandina d2 | |
| ECSP11010754A (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
| AR072840A1 (es) | Uso de reguladores del crecimiento de plantas para reducir el amarillamiento de las hojas de planta relacionado con el acido abscisico | |
| PT2139334E (pt) | Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos | |
| UA113756C2 (xx) | Топічні композиції, що містять фіпроніл і перметрин, та способи їх застосування | |
| BR112012017476A2 (pt) | composto, composição, método para preparar uma composição, uso de um composto, e, métodos para tratar doenças, para inibir um alérgico peptidase do ácaro da poeira, para exterminar ácaros, para controlar uma população de ácaros | |
| EA201491213A1 (ru) | Антагонисты trpm8 | |
| MX2014004464A (es) | Insecticida líquido que incluye tierra de diatomeas. | |
| HRP20240276T1 (hr) | 3-beta-(4-metoksibenzilloksi)pregn-5-en-20-on za uporabu u liječenju poremećaja povezanih s kanabinoidima | |
| BR112015020789A2 (pt) | método para controlar perfil de superfície de um ou mais cilindros de trabalho de laminador e dispositivo de resfriamento para um ou mais cilindros de trabalho de laminador | |
| UY31919A (es) | Derivados de dibenzotiazepinas y sus usos-424 | |
| MX2010004830A (es) | Compuestos de 1,2,4, -triazin- 3,5-diona para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3. | |
| NZ596168A (en) | Use of delta-tocopheryl-carbohydrate as a depigmenting agent | |
| WO2013030669A3 (en) | Compositions comprising thymoquinone for the treatment of inflammatory diseases | |
| MX2016013680A (es) | Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos. |